Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06916767 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma
A Phase 1 study of Refractory Lymphoma and Relapsed CLL, sponsored by Paolo Caimi, MD.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT06916767 is a Phase 1 study of Refractory Lymphoma and Relapsed CLL that is actively recruiting participants, run by Paolo Caimi, MD. The registered enrollment target is 18 participants, below the 36-participant average among 39 other Refractory Lymphoma trials with a reported enrollment target (50% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06916767, a Phase 1 study of Refractory Lymphoma and Relapsed CLL, is actively recruiting participants, sponsored by Paolo Caimi, MD.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
CAR-T cell treatment of refractory lymphoma has shown success, particularly with CD-19 targeted CAR-T cells, however, many participants are refractory or relapse after response. Responses are more limited in CLL/SLL, possibly secondary to the suppressive effect of circulating B cells on T cell function. BAFF receptor is a target that has been explored in CLL. Preclinical data indicates that CAR- T cells expressing B-cell activating factor (BAFF) can be another effective strategy to treat refractory CLL. This study aims to explore the efficacy of LMY-920 a BAFF-ligand CAR T cells with depletion of B cells with Obinutuzumab prior to apheresis.
Conditions Studied
Interventions
- DRUG Obinutuzumab
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG BAFF CAR-T
Study Locations (1)
Ohio
- Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2025-07-15 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06916767
The ClinicalTrials.gov registry entry for NCT06916767 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 36-participant average among 39 other Refractory Lymphoma trials with a reported enrollment target (50% lower). The listed sponsor is Paolo Caimi, MD, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Refractory Lymphoma appearing as the primary indexed condition, and to 4 interventions - of which Obinutuzumab is the first listed.
NCT06916767 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT06916767 about?
NCT06916767 is a clinical study titled "Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma". CAR-T cell treatment of refractory lymphoma has shown success, particularly with CD-19 targeted CAR-T cells, however, many participants are refractory or relapse after response. Responses are more limited in CLL/SLL, possibly secondary to the suppressive effect of circulating B cells on T cell funct...
What is the current status of trial NCT06916767?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2025-07-15. Estimated completion is 2027-12-31.
What conditions does trial NCT06916767 study?
This clinical trial studies the following conditions: Refractory Lymphoma, Relapsed CLL, Refractory CLL.
What interventions are being tested in trial NCT06916767?
The interventions under investigation include: Obinutuzumab (DRUG), Cyclophosphamide (DRUG), Fludarabine (DRUG), BAFF CAR-T (DRUG).
Who is sponsoring clinical trial NCT06916767?
This trial is sponsored by Paolo Caimi, MD, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06916767 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Refractory Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Avo In R/R And Previously Untreated MCL
RECRUITING · Phase 1
-
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
RECRUITING · Phase 1
-
Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
COMPLETED · Phase 1
-
Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas
COMPLETED · Phase 1
-
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.